PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform that is intended to treat infections in chronic and acute wounds, announced today that the Oculus development team completed meetings this past week in Beijing, China with Chinese partners at China Bao Tai and Sinopharm regarding commercialization plans for the product launch of Microcyn Technology in China.
